₹11,995/dose, with dispatches having started. Analysts at a domestic brokerage say the opportunity is huge and even if the company targets 1 crore patients, the size would be as large as their domestic business.In another development, Zydus Cadila entity is to sell its India-focused Animal Health Business to Multiples Alternate Asset Management-led consortium.
The sale of the business would fetch about Rs2,920 crore on a slump sale basis. As per analysts at Motilal Oswal Financial Services Ltd, the business had sales of Rs600 crore (up 17% YoY) and an EBITDA margin of 25% ( up 800bps YoY) in FY21.
This implies EV/sales of 5times and EV/EBITDA of 19 times. Analysts feel valuations are decent considering its leadership positions across.